Discontinued — last reported Q4 '18
Products & Services · License Agreement Additional Milestone Payments
LG3Program — License Agreement Additional Milestone Payments
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ4 2018
Last reportedQ4 2018May 5, 2020
How to read this metric
An increase indicates successful advancement of the drug program through regulatory or clinical stages, while a decrease may suggest delays or failure to meet contractual performance targets.
Detailed definition
This metric represents the revenue recognized from contingent payments triggered by the achievement of specific clinical...
Peer comparison
Comparable to milestone revenue or contingent consideration recognized by other biotechnology firms engaged in out-licensing or collaborative drug development partnerships.
Metric ID:
incy_segment_lg3program_license_agreement_additional_milestone_paymentsSimilar Metrics at Other Companies
Frequently Asked Questions
- What does lg3program — license agreement additional milestone payments mean?
- Revenue earned from achieving specific development or sales goals as defined in a drug licensing agreement.